O. Faure

发表

Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002, The Journal of Immunology.

Induction of multiple CD 8 + T cell responses against the inducible Hsp 70 employing an Hsp 70 oligoepitope peptide

F. Lemonnier, I. Miconnet, J. Abastado, 2022 .

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

F. Lemonnier, I. Miconnet, S. Chouaib, 2003, Cancer research.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

A. Nardin, J. Abastado, O. Faure, 2006, Current cancer drug targets.

Broad-Spectrum Tumor Immunotherapy-A 12 Tumor Antigens : Implication in a MAGE-A 1 ,-A 2 ,-A 3 ,-A 4 ,-A 6 ,-A 10 , and HLA-A * 0201-Restricted Epitope Shared by Generation of CTL Recognizing an

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002 .

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

J. Soria, F. Lemonnier, I. Miconnet, 2006, Cancer Immunology, Immunotherapy.

HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, L. Nadler, 2002, The Journal of Immunology.

Novel Targets for Broad Spectrum Tumor and hTERT Cryptic Epitopes as neu HER-2 /

F. Lemonnier, S. Chouaib, L. Nadler, 2002 .

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

P. Opolon, J. Davoust, F. Lemonnier, 2004, The Journal of clinical investigation.

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA‐A*0201‐restricted epitopes

F. Lemonnier, I. Miconnet, J. Abastado, 2004, International journal of cancer.

A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.

F. Lemonnier, S. Chouaib, Steven G. Smith, 2007, Cancer research.

Vaccine Targeted to Her-2 / ErbB2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge

F. Lemonnier, S. Chouaib, Steven G. Smith, 2007 .